

Jung Il Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2462525/publications.pdf>

Version: 2024-02-01

57
papers

1,016
citations

394421

19
h-index

477307

29
g-index

61
all docs

61
docs citations

61
times ranked

1900
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreased density of interstitial cells of Cajal and neuronal cells in patients with slow-transit constipation and acquired megacolon. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1292-1298.	2.8	79
2	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. <i>Liver International</i> , 2015, 35, 2246-2255.	3.9	66
3	Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 116-124.	0.4	63
4	Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 170-178.	8.9	49
5	Survival outcome of patients with spontaneously ruptured hepatocellular carcinoma treated surgically or by transarterial embolization. <i>World Journal of Gastroenterology</i> , 2013, 19, 4537.	3.3	49
6	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	3.7	43
7	Liver injury in acute hepatitis A is associated with decreased frequency of regulatory T cells caused by Fas-mediated apoptosis. <i>Gut</i> , 2015, 64, 1303-1313.	12.1	38
8	Prevalence of Barrett's esophagus in an urban Korean population: a multicenter study. <i>Journal of Gastroenterology</i> , 2003, 38, 23-27.	5.1	36
9	Development of a small animal model to simulate clinical stereotactic body radiotherapy-induced central and peripheral lung injuries. <i>Journal of Radiation Research</i> , 2014, 55, 648-657.	1.6	33
10	Apoptosis of hepatic stellate cells in carbon tetrachloride induced acute liver injury of the rat: analysis of isolated hepatic stellate cells. <i>Journal of Hepatology</i> , 2003, 39, 960-966.	3.7	32
11	Role of Smad3 in platelet-derived growth factor-C-induced liver fibrosis. <i>American Journal of Physiology - Cell Physiology</i> , 2016, 310, C436-C445.	4.6	29
12	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469.	2.8	26
13	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 475-482.	3.3	26
14	MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4919-4928.	2.3	26
15	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Cancer Medicine</i> , 2019, 8, 5023-5032.	2.8	25
16	Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 432-434.	3.7	24
17	Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study. <i>Oncotarget</i> , 2017, 8, 113213-113224.	1.8	24
18	Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice. <i>Experimental and Molecular Medicine</i> , 2014, 46, e127-e127.	7.7	23

#	ARTICLE	IF	CITATIONS
19	Progression of diet induced nonalcoholic steatohepatitis is accompanied by increased expression of kruppel-like-factor 10 in mice. <i>Journal of Translational Medicine</i> , 2014, 12, 186.	4.4	22
20	A Modified Protocol of Diethylnitrosamine Administration in Mice to Model Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5461.	4.1	21
21	The Clinical Outcomes of Lower Gastrointestinal Bleeding Are Not Better than Those of Upper Gastrointestinal Bleeding. <i>Journal of Korean Medical Science</i> , 2016, 31, 1611.	2.5	18
22	Selective deletion of hepatocyte platelet-derived growth factor receptor $\hat{\pm}$ and development of liver fibrosis in mice. <i>Cell Communication and Signaling</i> , 2018, 16, 93.	6.5	17
23	Current role of transient elastography in the management of chronic hepatitis B patients. <i>Ultrasonography</i> , 2017, 36, 86-94.	2.3	17
24	Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study. <i>Oncologist</i> , 2019, 24, e653-e661.	3.7	16
25	Platelet-derived growth factor receptor $\hat{\pm}$ in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis. <i>Oncotarget</i> , 2017, 8, 39534-39546.	1.8	16
26	Long-Term Follow-Up of Patients after Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis. <i>Cell Transplantation</i> , 2017, 26, 1059-1066.	2.5	15
27	Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2019, 25, 4959-4969.	3.3	13
28	Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1481-1491.	4.9	12
29	Impact of postoperative hepatitis $\langle \text{sc} \rangle \text{B} \langle / \text{sc} \rangle$ virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1019-1027.	2.8	12
30	Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea. <i>Medicine (United States)</i> , 2016, 95, e3896.	1.0	12
31	Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1348-1355.e2.	4.4	12
32	Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). <i>Clinical and Molecular Hepatology</i> , 2016, 22, 443-449.	8.9	10
33	Usefulness of the Controlled Attenuation Parameter for Detecting Liver Steatosis in Health Checkup Examinees. <i>Gut and Liver</i> , 2015, 9, 405-10.	2.9	10
34	A single adenovirus-mediated relaxin delivery attenuates established liver fibrosis in rats. <i>Journal of Gene Medicine</i> , 2016, 18, 16-26.	2.8	9
35	Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. <i>Cancers</i> , 2019, 11, 425.	3.7	8
36	Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 315-324.	2.3	8

#	ARTICLE	IF	CITATIONS
37	Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 4567.	3.7	8
38	Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1052-1060.	2.0	7
39	Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t)ide analogue-induced hepatitis B e antigen Seroclearance. <i>BMC Gastroenterology</i> , 2020, 20, 113.	2.0	7
40	Addition of liver stiffness enhances the predictive accuracy of the PAGEaB model for hepatitis Bâ€related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 919-927.	3.7	7
41	Antiviral Therapy in Patients With Chronic Hepatitis C-related Hepatocellular Carcinoma Responding to Palliative Treatment. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 557-562.	2.2	6
42	Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir+Asunaprevir therapy in Korean patients with genotype 1b hepatitis C. <i>Virology Journal</i> , 2017, 14, 164.	3.4	5
43	Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBsAg Seroclearance. <i>Digestive Diseases and Sciences</i> , 2022, 67, 321-328.	2.3	5
44	Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a FavorableIL28BAllele-Prevalent Area. <i>Intervirolology</i> , 2013, 56, 178-183.	2.8	4
45	Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy. <i>Scientific Reports</i> , 2019, 9, 15628.	3.3	4
46	Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1612.	3.7	4
47	Risk assessment of hepatocellular carcinoma and liverâ€related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	2.0	4
48	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893.	1.6	4
49	Reactivation of Hepatitis B Virus in Patients with Rheumatologic Disease Treated with Biologic Disease Modifying Anti-rheumatic Drugs: Screening and Treatment. <i>Journal of Rheumatic Diseases</i> , 2015, 22, 282.	1.1	3
50	Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study. <i>Radiation Oncology</i> , 2017, 12, 133.	2.7	2
51	Pharmacokinetics and safety of evogliptin in hepatically impaired patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 87, 2757-2766.	2.4	2
52	Role of Periostin in Hepatocellular Carcinoma: The Importance of Tumor Microenvironment. <i>Gut and Liver</i> , 2016, 10, 871-872.	2.9	2
53	Fabry's disease: a case report and review of literatures reported in Korea. <i>Yonsei Medical Journal</i> , 1998, 39, 67.	2.2	1
54	Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 576-584.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report. <i>Journal of Liver Cancer</i> , 2022, 22, 84-90.	1.1	1
56	Regional Diversity of Hepatitis C Virus Prevalence: Seeking for Culture Specific Mode of Transmission. <i>Gut and Liver</i> , 2014, 8, 337-338.	2.9	0
57	Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions. <i>Gut and Liver</i> , 2022, 16, 497-498.	2.9	0